MARKET

BCRX

BCRX

Biocryst Pharmaceuticals Inc
NASDAQ
8.32
+0.22
+2.65%
Opening 13:05 10/28 EDT
OPEN
8.03
PREV CLOSE
8.10
HIGH
8.45
LOW
8.01
VOLUME
1.72M
TURNOVER
--
52 WEEK HIGH
11.22
52 WEEK LOW
6.23
MARKET CAP
2.12B
P/E (TTM)
-5.5286
1D
5D
1M
3M
1Y
5Y
1D
BioCryst Pharmaceuticals (BCRX) Wins FDA Nod As ORLADEYO Bulls Ask If The Stock Is A Bargain
Simply Wall St · 10h ago
Weekly Report: what happened at BCRX last week (1019-1023)?
Weekly Report · 2d ago
Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade
Benzinga · 5d ago
FDA Clears Oral Pellets That Could Be A Game Changer For BioCryst Pharmaceuticals (BCRX)
Simply Wall St · 6d ago
BioCryst wins FDA nod for Orladeyo oral pellets
Seeking Alpha · 10/21 15:04
Analysts Offer Insights on Healthcare Companies: Actinium Pharmaceuticals (ATNM), BioMarin Pharmaceutical (BMRN) and BioCryst (BCRX)
TipRanks · 10/21 13:01
BioCryst Wins FDA Approval For Orladeyo Oral Pellets In HAE Patients Aged 12 And Older
NASDAQ · 10/21 12:03
BioCryst announces FDA approval for Orladeyo sNDA
TipRanks · 10/21 11:30
More
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of HAE attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX17725, navenibart, Avoralstat, STAR-0310, RAPIACTA (peramivir injection) and PERAMIFLU (peramivir injection). The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older. Peramivir injection is also approved in Canada (RAPIVAB), Australia (RAPIVAB), Japan (RAPIACTA), Taiwan (RAPIACTA), and Korea (PERAMIFLU). It has also obtained an early-stage program for atopic dermatitis (AD), STAR0310.

Webull offers BioCryst Pharmaceuticals Inc stock information, including NASDAQ: BCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCRX stock methods without spending real money on the virtual paper trading platform.